DelveInsight's "Primary Biliary Cholangitis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Primary Biliary Cholangitis, historical and forecasted epidemiology as well as the Primary Biliary Cholangitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the Primary Biliary Cholangitis Market Share @ Primary Biliary Cholangitis Market Outlook
Key Takeaways form the Primary Biliary Cholangitis Market Report
- DelveInsight’s forecasting report of PBC includes the Epidemiology analysis and forecast of the US, EU4 and the UK, and Japan. As per our analysis, the US had the highest diagnosed prevalent cases of PBC in 2023, which are expected to rise, at a decent CAGR during the forecasted period (2024–2034).
- In 2023, among EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Germany accounted for the highest number of diagnosed prevalent cases of PBC i.e. around 34 thousand cases which is expected to increase by 2034.
- The incidence of PBC rises with age, and is particularly higher among individuals aged 40 to 70 years. Our estimates for 2023 indicate a distribution of cases by age groups: approximately 14 thousand cases were observed in individuals under 40 years old, with numbers increasing steadily with age. The highest number of cases, totaling 87 thousand, occurred in the 40–70 age bracket, while 43 thousand cases were reported in individuals aged 70 and above in the US.
- Our analysis indicates a higher prevalence of PBC among females compared to males, with distribution rates of 82% and 18% respectively, in the US in 2023.
- The leading Primary Biliary Cholangitis Companies such as Intercept Pharmaceuticals, CymaBay Therapeutics, Genfit, Genkyotex SA, Zydus Cadila, Cara Therapeutics, HighTide Therapeutics, Albireo, GlaxoSmithKline, and others.
- Promising Primary Biliary Cholangitis Therapies such as Elafibranor, Saroglitazar Magnesium, CNP-104, Setanaxib, Seladelpar, Volixibat, Bezafibrate, EP547, Linerixibat, and others.
Navigate the complexities of the Primary Biliary Cholangitis Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Primary Biliary Cholangitis Market Forecast. Click here to get more insights @ Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Epidemiology Segmentation in the 7MM
- Total Primary Biliary Cholangitis Diagnosed Prevalent Cases
- Primary Biliary Cholangitis Gender-specific Cases
- Primary Biliary Cholangitis Age-specific Cases
Download the report to understand which factors are driving Primary Biliary Cholangitis Epidemiology trends @ Primary Biliary Cholangitis Prevalence
Primary Biliary Cholangitis Marketed Drugs
- OCALIVA: Intercept Pharmaceuticals
OCALIVA offers a novel treatment approach for PBC by targeting FXR and has shown efficacy in reducing ALP levels and improving outcomes for patients who have not responded to or cannot tolerate UDCA, highlighting its significance as an alternative therapy in the management of PBC. OCALIVA has received accelerated approval from the FDA for the treatment of PBC, demonstrating its potential to address serious conditions and providing earlier patient access to promising new drugs while confirmatory trials are ongoing.
Primary Biliary Cholangitis Emerging Drugs
- Seladelpar: CymaBay Therapeutics
Seladelpar, developed by CymaBay Therapeutics, is an oral, selective peroxisome proliferator-activated receptor (PPAR) delta agonist aimed at treating primary biliary cholangitis (PBC). It regulates crucial metabolic and liver disease pathways, impacting bile acid synthesis, inflammation, fibrosis, and lipid metabolism. Clinical studies demonstrate its efficacy in reducing biomarkers associated with adverse outcomes in PBC, alongside improving pruritus. Unlike other PPAR agonists, seladelpar acts on various liver cell types, uniquely affecting PBC pathobiology. It has garnered FDA Breakthrough Therapy Designation and EMA Priority Medicines (PRIME) status, with an NDA submitted to the FDA for PBC treatment, underscoring its promising potential and regulatory recognition.
Get In-Depth Knowledge on Primary Biliary Cholangitis Market Trends and Forecasts with DelveInsight @ Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Treatment objectives aim to decelerate the advancement of the disease and alleviate associated symptoms such as itching, osteoporosis, and sicca syndrome. Liver transplantation stands as the singular life-saving procedure available. Ursodeoxycholic acid (UDCA) stands as the primary medication employed to impede disease progression. Patients in the initial stages of the disease witness clinical, biochemical, and histological enhancements. Studies indicate that UDCA postpones the necessity for transplantation and prolongs life. However, its effectiveness in later stages, particularly in cases of cirrhosis, remains uncertain.
Primary Biliary Cholangitis Companies
Intercept Pharmaceuticals, CymaBay Therapeutics, Genfit, Genkyotex SA, Zydus Cadila, Cara Therapeutics, HighTide Therapeutics, Albireo, GlaxoSmithKline, and others.
Scope of the Primary Biliary Cholangitis Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Primary Biliary Cholangitis Companies- Intercept Pharmaceuticals, CymaBay Therapeutics, Genfit, Genkyotex SA, Zydus Cadila, Cara Therapeutics, HighTide Therapeutics, Albireo, GlaxoSmithKline, and others.
- Primary Biliary Cholangitis Therapies- Elafibranor, Saroglitazar Magnesium, CNP-104, Setanaxib, Seladelpar, Volixibat, Bezafibrate, EP547, Linerixibat, and others.
- Primary Biliary Cholangitis Market Dynamics: Primary Biliary Cholangitis Market Drivers and Barriers
- Primary Biliary Cholangitis Unmet Needs, KOL's views, Analyst's views, Primary Biliary Cholangitis Market Access and Reimbursement
Gain a strategic edge in the Primary Biliary Cholangitis Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Primary Biliary Cholangitis Market Forecast. Click here to lead in advancements @ Primary Biliary Cholangitis Clinical Trials Assessment
Table of Content
1. Key Insights
2. Executive Summary of Primary Biliary Cholangitis
3. Competitive Intelligence Analysis for Primary Biliary Cholangitis
4. Primary Biliary Cholangitis: Market Overview at a Glance
5. Primary Biliary Cholangitis: Disease Background and Overview
6. Patient Journey
7. Primary Biliary Cholangitis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Primary Biliary Cholangitis Unmet Needs
10. Key Endpoints of Primary Biliary Cholangitis Treatment
11. Primary Biliary Cholangitis Marketed Products
12. Primary Biliary Cholangitis Emerging Therapies
13. Primary Biliary Cholangitis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Primary Biliary Cholangitis Market Outlook
16. Access and Reimbursement Overview of Primary Biliary Cholangitis
17. Primary Biliary Cholangitis KOL Views
18. Primary Biliary Cholangitis Market Drivers
19. Primary Biliary Cholangitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage
